TMOD4

Across TCGA pan-cancer cohorts, TMOD4 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated TMOD4 data layer compared with 3 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TMOD4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMOD4 expression acts as an unfavorable survival marker, although some lineages such as STAD and SCLC show a favorable association.

MESO, BLCA, and CHOL are the cancer types where TMOD4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.044	0.566	<.001	108	view →
BLCA	DFS	Tertile	All	0.094	0.594	.001	63	view →
CHOL	OS	Tertile	All	0.019	0.800	<.001	54	view →
PAAD	OS	Tertile	All	0.138	0.590	<.001	27	view →
UCS	OS	Tertile	All	0.269	0.693	.018	18	view →
GBM	OS	Tertile	All	0.069	0.415	<.001	18	view →
LAML	DFS	Tertile	All	0.231	0.594	.019	18	view →
STAD	OS	Tertile	III,IV	1.000	0.368	.045	9	view →
SCLC	DFS	Median	III,IV	0.402	0.134	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TMOD4–MESO (OS)

Open the MESO breakdown →